| arznei-telegramm® 04/2016 |
THERAPY FROM A CRITICAL VIEWPOINT |
| Polypill with rosuvastatin, candesartan and hydrochlorothiazide failed for the time being |
NEW ON THE MARKET |
| Mepolizumab (NUCALA) for severe refractory eosinophilic asthma |
| Brivaracetam (BRIVIACT) against partial-onset seizures |
a-t READER'S QUESTIONS AND COMMENTS |
| Vaccination against tick-borne encephalitis: how often to booster? |
| Prophylactic antibiotics prior to procedures in patients with prosthetic joints? |
| Oral g-strophanthin (ouabain) for heart patients? |
IN BRIEF |
| Painkillers against uncomplicated cystitis? |
| Olmesartan (OLMETEC, VOTUM) is no longer reimbursed in France |
| Progressive multifocal leukoencephalopathy with dimethyl fumarate (TECFIDERA) |
CURRENT ADR NETWORK REPORT |
| Tinnitus with topical green tea extract (VEREGEN) |
SIDE EFFECTS | Abuse of the antihistamines diphenhydramine (e.g. EMESAN) and dimenhydrinate (e.g. VOMEX A) |